Anupam Rasayan India Ltd (BSE: 543275 / NSE: ANURAS) reported strong growth in revenue and profitability during the quarter ended June 30, 2025, driven by higher exports, recovery in agrochemicals and continued momentum across pharmaceutical and polymer businesses.
Consolidated total revenue for Q1 FY26 rose 89% year-on-year to ₹4,907 million, while consolidated EBITDA increased 118% to ₹1,292 million. Profit after tax stood at ₹485 million, up 297% compared with the corresponding quarter last year.
Business overview
Anupam Rasayan is a specialty chemicals manufacturer focused on custom synthesis and complex chemical intermediates used across life sciences and performance materials. The company operates six manufacturing facilities with total capacity exceeding 30,000 metric tonnes and serves over 75 global clients, including 31 multinational corporations.
Its product portfolio includes 80 complex products spanning agrochemicals, personal care, pharmaceuticals, polymers and electronic chemicals. The company employs over 1,700 people and operates a DSIR-recognised R&D centre supported by more than 90 research professionals.
Financial performance — Q1 FY26
Consolidated revenue from operations increased to ₹4,858 million from ₹2,542 million in Q1 FY25. EBITDA margin improved to 26% from 23%, while PAT margin rose to 10% from 5%.
On a standalone basis, total revenue rose 89% year-on-year to ₹3,205 million, with EBITDA expanding 133% to ₹991 million. Standalone PAT stood at ₹297 million compared with ₹14 million in Q1 FY25.
Gross margins declined to 50% at the consolidated level from 60% in the prior-year period, primarily reflecting higher raw material consumption.
Revenue mix and operational highlights
Life science specialty chemicals accounted for 88% of revenue, while performance materials contributed 12%. Segment-wise, agrochemicals represented 57% of revenue, pharmaceuticals 24%, personal care 7%, and performance materials 12%.
Management indicated that exports accounted for 58% of total revenue during the quarter, with improving demand trends from the United States and Japan markets.
The company added one new product during the quarter, taking the cumulative count to 80 products.
Order book and growth pipeline
Anupam Rasayan reported an order book of ₹14,646 crore, supported by multiple long-term contracts and letters of intent with global multinational companies. Several new agreements signed with Japanese and US-based customers are scheduled for commercialization between FY26 and FY28.
Growth drivers highlighted by the company include expansion of polymer and pharmaceutical portfolios, execution of signed contracts, and increased focus on fluorination chemistry supported by backward integration with Tanfac Industries.
R&D and strategic expansion
The company reported R&D investments of around ₹55 crore over the last five years and identified more than 65 molecules in pharma and polymer under R&D and pilot stages.
Management also highlighted opportunities in fluorination chemistry, targeting a potential revenue opportunity of $220–260 million over time through high-value specialty molecules.
Risks and constraints
Performance remains linked to execution of long-term contracts, raw material costs, export demand, and the pace of commercialization of pipeline products and specialty chemistry projects.
Outlook
Management stated that sectoral trends remain favourable, supported by growth in pharmaceuticals and polymers along with recovery in agrochemicals, and expects continued momentum from export-led growth and execution of contracted order pipelines.